Fenwick Represented Morphic in its $103.5M Initial Public Offering

Fenwick & West represented Morphic Holding (MORF), a biopharmaceutical company discovering and developing oral small-molecule integrin therapeutics, in its initial public offering of 6.9 million shares at a price of $15 per share, raising gross proceeds of $103.5 million.

The underwriters on the Morphic offering are Jefferies LLC, Cowen and Company LLC, BMO Capital Markets Corp. and Wells Fargo Securities LLC.

The Fenwick transaction team included corporate lawyers: Robert Freedman, Effie Toshav, Julia Forbess, Alice Lin, Morgan McDonell, Emily Yi, Christian Olano and Ellen Welichko; executive compensation and employee benefits lawyers: Matt Cantor, Laura McIntyre, Corinne Nhaissi; intellectual property lawyers: Stefano Quintini and Amy Manning.